We’ve known for years that different patients respond to different treatments. But for the vast majority of diseases, we’ve had no way of knowing which treatment will work best for the individual. The result? Drugs are developed for what is believed to be the “average patient,” even though there’s no such thing, and patients are prescribed drug after drug until, hopefully, they find one that works. Meanwhile, they’re putting their lives on hold while their disease worsens and billions of dollars are wasted in prescription costs. Now, with our breakthrough ability to determine which drug will work best for each patient, we can do better.
The path to effective treatment has always been long and harrowing.
So, we created a map.
Most diseases are caused by proteins not being produced and controlled correctly in our cells. To predict how a given patient will respond to a specific treatment, we have to determine if the drug actually targets the patient’s abnormal protein levels. DNA carries the instructions for creating proteins, but only RNA – the messenger that signals which and how much of a protein should be produced – can inform us of an individual patients’ protein levels.
While the ability to interpret RNA data has eluded scientists for decades, our team took a new approach, combining RNA expression data with a decade-in-the-making map of protein interactions to create a revolutionary new platform. Now, we’re able to decipher the biology of each patient’s disease and predict their response to specific treatments using his or her own RNA data.
Through a simple blood test, our platform interprets a patient’s RNA data to predict which drug will work best. And when the data shows that no existing drug works for a patient, we use that data to fuel the development of new therapies with a clear unmet medical need. From more accurate diagnostics to transformative approaches to drug development, each advancement made through our data-driven platform pushes our entire field beyond average and into a new era of individual patient treatment.
Through a simple blood test, our diagnostics interpret a patient’s RNA data to predict which drug will work best from day one.
Our network medicine platform identifies the molecular signature of individual patients and determines which existing drug or new drug target will treat each patient most effectively.
Fueled by our platform and the data from our diagnostics, we develop new therapies for patients who do not respond to current therapies in the market.